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Abstract 
Background: Many general anesthetics were discovered empirically, but primary screens to 
find new sedative-hypnotics in drug libraries have not used animals, limiting the types of drugs 
discovered.  We hypothesized that a sedative-hypnotic screening approach using zebrafish 
larvae responses to sensory stimuli would perform comparably to standard assays, and 
efficiently identify new active compounds. 
Methods: We developed a binary outcome photomotor response assay for zebrafish larvae 
using a computerized system that tracked individual motions of up to 96 animals 
simultaneously.  The assay was validated against tadpole loss-of-righting-reflexes, using 
sedative-hypnotics of widely varying potencies that affect various molecular targets.  374 
representative compounds from a larger library were screened in zebrafish larvae for hypnotic 
activity at 10 µM.  Molecular mechanisms of hits were explored in anesthetic-sensitive ion 
channels using electrophysiology, or in zebrafish using a specific reversal agent.   
Results: Zebrafish larvae assays required far less drug, time and effort than tadpoles.  In 
validation experiments, zebrafish and tadpole screening for hypnotic activity agreed 100% (n = 
11; p =0.002) and potencies were very similar (Pearson correlation, r > 0.999).  Two reversible 
and potent sedative-hypnotics were discovered in the library subset.  CMLD003237 (EC50 ~ 11 
µM) weakly modulated γ-aminobutyric acid type A receptors and inhibited neuronal nicotinic 
receptors.  CMLD006025 (EC50 ~ 13 µM), inhibited both n-methyl-D-aspartate and neuronal 
nicotinic receptors.  
Conclusions: Photomotor response assays in zebrafish larvae are a mechanism-independent 
platform for high-throughput screening to identify novel sedative-hypnotics.  The variety of 
chemotypes producing hypnosis is likely much larger than currently known.  
[246 words]  
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Introduction:  General anesthesia is an essential tool in modern medicine and there is growing 
interest in developing new sedative-hypnotics with improved clinical utility 1,2.  Current and past 
clinical sedative-hypnotics represent a variety of anesthetic chemotypes (volatile ethers, 
barbiturates, phenylacetates, alkyl phenols, arylcyclohexylamines, imidazoles, and steroids), 
many identified by empiric observation, before 1980.  Most new hypnotics in clinical 
development are modifications or reformulations of these drugs 1.   
Drug libraries may contain many more un-discovered sedative-hypnotics.  Several screening 
strategies to identify hypnotics have been reported, most based on established molecular 
targets of anesthetics, particularly GABAA receptors.  Direct target-based screening approaches 
detect modulation of specific GABAA receptor subtypes expressed in cells 3-6.  In silico screening 
approaches calculate binding energies between candidate ligands and pharmacophores derived 
from high-resolution structures of GABAA receptors or homologs 7-9.  Another drug screening 
strategy detected displacement of a fluorescent anesthetic from horse apoferritin binding sites 
formed among α-helical bundles, similar to those in GABAA receptors 10,11. These indirect 
hypnotic discovery strategies have used secondary electrophysiological tests for GABAA 
receptor modulation. 
However, not all clinical anesthetics modulate GABAA receptors 12,13.  Many sedative-hypnotics 
apparently act via other molecular targets 14,15, and these would likely be missed by target-
based screening strategies.  
Stimulus-response tests in animals potentially represent a mechanism-independent screening 
approach for sedative-hypnotic drug activity.  The most common such test in vertebrates is loss-
of-righting-reflexes (LoRR), in which drug-exposed animals are placed supine and observed for 
return to the normal prone or four-leg standing position.  Accurate pharmacodynamic 
measurements using LoRR tests require steady-state drug concentrations in an animal’s 
nervous system.  In rodents, establishing steady-state drug concentrations in tissues is easy 
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with inhaled agents delivered at defined partial pressures, but very difficult with intravenous 
agents.  Conversely, steady-state concentrations of non-volatile drugs are easily established in 
water-breathing aquatic vertebrates immersed in drug solutions.  Thus, Xenopus tadpoles are 
widely used for LoRR testing of intravenous sedative-hypnotics, but this approach is impractical 
for primary sedative-hypnotic screening in large numbers of drugs.  In contrast, young zebrafish 
have proven useful for high-throughput bioassays of psycho-active drugs in libraries 16,17, but 
have not been used to screen specifically for new sedative-hypnotics. 
Here, we describe development of an approach to assess sedative-hypnotic drug effects in up 
to 96 zebrafish larvae simultaneously using computer-controlled stimuli and quantification of 
video-monitored motor responses.  Automated zebrafish larva hypnosis assays based on 
photomotor responses perform nearly identically to manual Xenopus tadpole LoRR tests for 
both hypnotic drug screening and potency determinations, while requiring far less material, time, 
and effort.  Applying this novel approach to a library of 374 organic small compounds identified 
two with reversible hypnotic activity.  These newly-identified sedative-hypnotics were further 
characterized in Xenopus tadpoles and a panel of molecular targets thought to mediate general 
anesthetic actions.  To explore translational potential, limited studies of intravenous 
administration in rats were also performed.  
[465 words]  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Sedative-Hypnotic Discovery Using Zebrafish Larvae  7 
Materials and Methods: 
Animals: Xenopus tadpoles and frogs were purchased from Xenopus One (Ann Arbor, MI, USA) 
and used with approval from the MGH IACUC.  Adult female frogs were used as a source of 
oocytes for two-micro-electrode voltage clamp electrophysiology, while tadpoles were used in 
manual loss-of-righting reflexes experiments, as previously described 18.  Zebrafish (Danio rerio, 
Tubingen AB strain) were used with approval from the MGH IACUC according to established 
protocols 19. Adult zebrafish were maintained in a specialized aquatic facility and mated to 
produce embryos and larvae as needed.  Embryos and larvae were maintained in petri dishes 
(140 mm diameter) filled with E3 medium (in mM: 5.0 NaCl, 0.17 KCl, 0.33 CaCl2, 0.33 MgSO4, 
2 HEPES at pH 7.4) in a 28.5C incubator under a 14/10 hour light/dark cycle, until used in 
experiments.  The density of embryos and larvae was less than 100 per dish.  Experiments 
were performed on zebrafish larvae at up to 7 days post-fertilization (dpf).  After either use in 
experiments or at 8 dpf, larvae were euthanized in 0.5% tricaine followed by addition of bleach 
(1:20 v:v).  Adult male Sprague-Dawley rats (250–400 gm) were purchased from Charles River 
Laboratories (Wilmington, MA, USA) and used with approval from the MGH IACUC in loss-of-
righting reflexes tests following intravenous drug administration.  Female rats were excluded 
from these studies, because their sensitivity to anesthetics varies with estrus cycle.  
Anesthetics and test compounds:  Etomidate was a gift from Professor Douglas Raines (MGH 
DACCPM, Boston, MA USA) and was prepared as a 2 mg/ml solution in 30% propylene 
glycol:water (v:v).  Alphaxalone was purchased from Tocris Bioscience (Bristol, UK).  Ketamine 
was purchased from Mylan Pharmaceuticals (Canonsburgh, PA USA) as a 10 mg/ml aqueous 
solution with 0.1 mg/ml benzethonium chloride as a preservative.  Dexmedetomidine was 
purchased from U.S. Pharmacopeia (Rockville, MD USA).  Propofol, pentobarbital, atipamezole 
and alcohols were purchased from Sigma-Aldrich (St. Louis, MO USA).  A set of 11 potent 
GABAA receptor modulators (see Table 1) 8,9 20-22 were gifts from Prof. Erwin Sigel (Institute of 
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Biochemistry and Molecular Medicine, University of Bern, Switzerland).  A chemical compound 
library “diversity” subset (374 compounds) was obtained from the Boston University Center for 
Molecular Discovery (directed by J.A.P.).  Physical properties 23,24 of these compounds are 
(mean ± sd; range): MW = 390 ± 101 (162 to 799); calculated LogP = 3.8 ± 1.6 (-0.13 to 12.9); 
polar surface area (Å2) = 66 ± 24 (16 to 160); H-bond donors = 0.87 ± 0.85 (0 to 5); and H-bond 
acceptors = 3.9 ± 1.5 (1 to 10).  Library compounds were provided on 384-well plates as 0.2 
micromoles dried film, and were reconstituted in 40 µL DMSO as 5 mM solutions.  Examination 
under a dissecting microscope was used to confirm complete dissolution of each compound. 
Chemicals:  Salts, buffers, γ-aminobutyric acid (GABA), acetylcholine (ACh), n-methyl-D-
aspartate (NMDA), and glycine, were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Loss of righting reflex assays in tadpoles and rats:  General anesthetic potency was assessed in 
Xenopus tadpoles at room temperature (22 ºC) as previously described 25.  For each anesthetic 
concentration studied, 8 or 10 animals were studied, based on previous experience.  Groups of 
4 to 5 tadpoles per container were placed in aqueous solutions (20 ml per animal; Fig 1A) 
containing known sedative-hypnotics or experimental compounds and tested every five minutes 
for 30 minutes.  Loss of righting reflexes (LoRR) was assessed by gently turning each animal 
supine using a polished glass rod.  Absence of swimming and/or turning prone within 5 seconds 
was counted as LoRR.  We recorded the LoRR count/total animals as a function of time after 
immersion in drug.  In screening tests for hypnotic activity, tadpoles were exposed to 10 µM 
drug.  Drugs were considered active if at least 50% of animals demonstrated LoRR after 30 min 
of exposure.  Concentration-dependent tadpole LoRR results were analyzed based on results at 
30 min.  Individual binary results (1 for LoRR; 0 otherwise) were tabulated and analyzed by 
fitting logistic functions [Y = Max* 10^(nH*log[drug])/(10^(nH*log[drug]) + 10^(nH*log[EC50]))] 
using non-linear least squares (Graphpad Prism 6.0).  We report mean EC50 (95% confidence 
interval).  After 30 minutes of drug exposure and final LoRR testing, animals were returned to 
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clean water and observed for 24 hours in order to establish whether drug effects were 
reversible.  In cases where animals did not survive for 24 hours after drug exposure, we 
repeated experiments in additional groups of animals to confirm whether toxic effects were 
consistently observed.  
For two novel compounds that produced reversible sedation and hypnosis in both zebrafish 
larvae and tadpoles, limited initial tests of hypnotic efficacy were also performed in rats, using 
LoRR assays 26.  Rats were briefly (< 5 min) anesthetized by isoflurane inhalation in order to 
place a 24 gauge intravenous catheter in a tail vein.  After recovery from isoflurane for at least 
60 minutes in room air, rats were gently restrained.  Before drug administration, intravenous 
cannulation was confirmed by gentle aspiration of blood and resistance-free injection of 0.25 ml 
normal saline. The desired dose of test drug in dimethyl sulfoxide vehicle (0.1– 0.5 ml) was then 
injected in < 5 s, followed by a 1 ml normal saline flush.  Immediately after drug delivery, rats 
were removed from restraint and turned supine.  A rat was judged to have LoRR if it failed to 
right (i.e. turn itself back onto all four paws) within 5 s after being turned.  Both the latency to 
LoRR after saline flush and the duration of LoRR, defined as the time from LoRR onset until the 
animal spontaneously returned to a four-paw upright stance, were measured with a stopwatch.  
Because our goal was to establish whether these drugs could induce hypnosis using limited 
available amounts of the test compounds, only one or two rats were studied at each dose.  
Zebrafish Larvae Photomotor Response Assays:  Using a 1000l pipetter fitted with a cut and 
fire-polished tip, single zebrafish larvae (7dpf, sex indeterminate) were placed into wells of a 
standard 96-well plate containing 150l E3 buffer.  Known anesthetics and test compound 
stocks were prepared in DMSO, and then diluted in E3 buffer to 4 times the desired final 
concentration. A multi-pipette was used to load 50 l of 4x solutions into wells, bringing the final 
volume to 200l (Fig 1B).  Final DMSO concentrations were no more than 0.2%.   
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Immediately after addition of drugs (< 5 min), the 96-well plate loaded with larvae was placed in 
a Zebrabox (Viewpoint Behavioral Systems, Montreal, Canada) and adapted at 28°C in the dark 
chamber for 15 min.  During experiments, activity of individual larvae was recorded with an 
infrared video camera and analyzed using Zebralab v3.2 software (Viewpoint Behavioral 
Systems).  Basal activity in the darkened chamber was recorded for 5-10 sec, followed by a 
0.2s exposure to a 500 lux white light stimulus, and another 5-10 s in the dark.  Each animal 
was tested in this manner up to 10 times at 3 min intervals.  Zebralab software quantifies each 
animal’s motor activity by assessing changes in infrared image pixel intensity (on a scale of 1 to 
256) of all pixels corresponding to the image area of its circular well, between sequential video 
sweeps (every 40 ms).  An activity score is calculated by summing the absolute values of pixel 
intensity changes over the whole well.  Activity integration is a Zebralab output that sums activity 
scores over multiple video sweeps during an experimentally defined epoch.  For larval 
photomotor response (PMR) experiments, we used activity integration epochs of 0.2 to 1.0 s 
and normalized activity scores for 0.2 s epochs (e.g. the activity score for a 1 s epoch was 
reduced 5-fold).   
To establish a binary PMR outcome, we calculated the mean and standard deviation for pre-
stimulus basal activity (5 to 10 s per trial, up to 10 trials, normalized to 0.2 s epochs) for 
individual larvae.  PMR for a single trial was scored as positive (1) if activity during any of the 
three 0.2 s epochs during and after the photic stimulus exceeded the upper 95% confidence 
interval (mean + 2 x sd) for basal activity.  Otherwise, PMR was scored as negative (0).  
Cumulative PMR probabilities for each larva were calculated by pooling single trial PMR results 
from multiple sequential trials.  For statistical analyses, results from all larvae in an exposure 
group were pooled.  D’Agonstino & Pearson normality tests performed on cumulative PMR 
probabilities from studies using 8 or more animals per group indicated normally distributed 
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results when not naturally skewed toward either 1.0 (in control conditions) or 0 (with high 
concentrations of hypnotics).   
Screening for Hypnotic Drug Activity Using Larval Zebrafish Photomotor Responses:  The 
hypnotic effects of compounds at 10 µM (in 0.2% DMSO) were tested in groups of 8 to 12 
zebrafish larvae.  Each plate included 6 to 10 test compounds, a negative control group in 0.2% 
DMSO, and a positive control group in 10 µM etomidate.  Individual larva single trial PMR 
responses were tabulated for four trials, and averaged to calculate cumulative PMR 
probabilities. The PMR probabilities for all larvae in a drug-exposed group were combined to 
calculate mean and variance (SD or 95% confidence intervals) statistics.  Drug-exposed group 
results were compared to those from the negative control (no drug) group using one-way 
ANOVA (GraphPad Prism 6.0) with Dunnett’s post-hoc test.  Pairwise p values were calculated 
using unpaired two-tailed Student’s t-tests.  Compounds that inhibited PMR relative to control 
with p < 0.05 (adjusted using a Bonferroni correction for multiple comparisons) were studied 
further to establish hypnotic potency and reversibility.   
To calculate the power of our drug screening approach, we performed an analysis as follows: 
Photomotor response experiments with no drug in 96 larvae tested four times each revealed 
mean cumulative PMR probability of 0.89 with standard deviation of 0.17 (see Results).  With 8 
larvae per group, and α = 0.005 (applying a Bonferroni correction for 10 comparisons to each 
control) in a two-tailed t-test, a power calculation (using G*Power v 3.08) indicated 0.95 
probability (1 - β) of detecting a 0.45 absolute (50% relative) reduction in PMR probability (effect 
size = 2.6). 
Concentration-Response Studies Using Larval Zebrafish Photomotor Responses:  Larvae in 
groups of 8 to 12 were exposed to either control (no drug) or varying concentrations of drug.  
When drug stock drug solution (usually > 100 mM) was in DMSO, all control and final drug 
solutions included the same DMSO concentrations (< 0.1%).  Cumulative PMR probability for 
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each animal was established as described above from four trials.  Results (mean with 95% 
confidence interval) for all animals in each exposure group were calculated and plotted against 
log[drug, M].  Concentration-dependent PMR inhibition was analyzed by fitting logistic functions 
to pooled PMR probability data using non-linear least squares (see above tadpole LoRR 
analysis).  We report mean hypnotic EC50 (95% confidence interval).   
Drug Effects on Spontaneous Activity of Zebrafish Larvae:  Spontaneous activity data from pre-
stimulus baseline periods was used to assess the sedative potency of tested drugs.  Activity 
integration values for all 25 0.2 s pre-stimulus epochs per trial were pooled across all four trials 
and all animals in a drug exposure group.  These data were used to calculate mean and 
variance (SD or 95% CI) statistics.  Combined spontaneous activity data were normalized to the 
mean value for no-drug controls on the same plate.  Spontaneous activity in drug-exposed 
larvae were compared to no-drug controls and drug-dependent inhibition of spontaneous activity 
was analyzed using logistic fits, as described above for PMR results.  
Drug Effect Reversibility in Zebrafish Larvae:  The reversibility of PMR inhibition was tested in 
zebrafish larvae exposed to the highest drug concentrations used in concentration-response 
studies.  These larvae were carefully transferred to petri dishes containing fresh E3 medium and 
placed in an incubator used to maintain embryos and larvae.  Larvae were repeatedly tested for 
motor reactivity to a gentle tap on the petri dish at 15 and 30 minutes after drug exposure, and 
again 24 hours later.  In cases where drug-exposed zebrafish larvae did not survive for 24 
hours, additional groups of animals were tested to establish whether toxic effects were 
reproducible.   
Library Hit Validation: Active library compounds from zebrafish screening were validated using 
new freshly-supplied aliquots of the original stock from BU-CMD. Compound identity and purity 
was confirmed using ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) 
with a “passing” threshold of 90% purity as measured using evaporative light scattering 
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detection (ELSD).  Activity and potency of the fresh aliquots were confirmed in zebrafish PMR 
assays.  Tadpole and rat LoRR assays were performed using freshly prepared compounds, 
generated using published methods, at >98% purity as determined by NMR and UPLC-MS 
analysis.  CMLD003237 was prepared according to the published protocol, which produces the 
(+) enantiomer in 90% enantiomeric excess and >11:1 diastereomeric ratio 27.  CMLD003237 
prepared for tadpole and rat studies was further purified by flash column chromatography to 
>20:1 diastereomeric ratio. CMLD006025 and its enantiomer CMLD011815 were prepared 
according to published protocols 28-30.  
Ion Channel Expression:  DNA plasmids encoding human N-methyl-D-aspartate (NMDA) 
receptor (NMDAR) subunits NR1B and NR2A were obtained from Prof. Steven Treistman 
(University of Massachusetts Medical School, Worcester, MA USA). Plasmids encoding the 
human neuronal nicotinic acetylcholine receptor (nnAChR) subunits α4 and β2 were obtained 
from Prof. James Patrick (Salk Institute, La Jolla, CA, USA). Plasmids encoding human HCN1 
channels were a gift from Prof. Peter Goldstein (Weill Cornell Medical College, New York, NY 
USA).  Human α1, β3, and γ2 GABAA receptor subunits were inserted into pCDNA3.1 
expression vectors (Thermo Fisher Scientific, Waltham, MA, USA).  Human glycine receptor α1 
subunit cDNA was cloned from whole brain mRNA (Thermo Fisher Scientific) using PCR and 
inserted into pCDNA3.1.  Capped messenger RNAs (mRNAs) were transcribed in vitro using 
mMessage Machine kits (Thermo Fisher Scientific). For NMDA receptor studies, oocytes were 
injected with 15ng in 1:1 mRNA mixtures of NR1B:NR2A;  for nnAChR studies, 15 ng of 
1α4:1β2;  for GABAA receptors, 5ng total of 1α:1β:5γ;  for HCN1 channels, 15 ng HCN1;  and for 
glycine receptors, 0.015 ng α1 subunit mRNA.  Oocytes were incubated in ND96 solution (in 
mM: 96 NaCl, 4 KCl, CaCl2 1.8, MgCl2 1.0, and HEPES 5, pH 7.5) supplemented with 100 μg/ml 
gentamicin at 18C for 48-96 hours before electrophysiology. 
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Voltage-clamp electrophysiology:  Two micro-electrode electrophysiology techniques for 
GABAARs, NMDARs and nnAChRs have been described previously 31,32.  Experiments were 
performed at 20 to 22 °C in ND96 buffer (Mg2+-free ND96 was used in NMDA receptor 
experiments).  Positive modulation of α1β3γ2L GABAA receptors was assessed using receptor 
activation with EC5 GABA (3 µM). Positive modulation of glycine α1 receptors was assessed 
with EC5 glycine (1 µM).  Inhibition of α4β2 neuronal nAChRs was tested using maximal 
activation conditions (1mM acetylcholine).  Inhibition of NMDA receptors was tested using 
maximal activation (100μM NMDA plus 10μM glycine) in Mg2+-free ND96.  Voltage-dependent 
HCN1 currents were stimulated using a previously described voItage-jump protocol, starting and 
ending at a holding level of -40 mV 33.  In all cases, oocytes were pre-exposed to drug for 30s 
before receptor activation.  Voltage-clamped currents were low-pass filtered at 1 kHz, digitized 
at 100 Hz, recorded, and analyzed offline to evaluate baseline-corrected peaks.  Peak currents 
were normalized to responses measured in the same cell without drug.  All hypnotic compounds 
were tested at 2 x EC50 for loss-of-righting-reflexes (LoRR) in zebrafish or tadpoles.  Drug 
effects on GABAA receptors were compared to those produced by 3.2 μM etomidate (2 x EC50) 
in the same cells.  Drug effects on glycine receptors and HCN1 channels were compared to 4.5 
µM propofol (2 x EC50).  Drug effects in NMDA and nnACh receptors were compared to 120 μM 
ketamine (2 x EC50) in the same cells.  The number of electrophysiological experiments needed 
to detect either a doubling of GABA or glycine receptor EC5 responses (an effect size of about 
3) or 30% inhibition of maximal responses in other channels (also an effect size of about 3) was 
determined to be 4, based on power analysis (using G*Power v 3.08) for a two-tailed t-test with 
1-β = 0.8 and α =0.025 (using a Bonferroni correction for 2 comparisons).  Thus, at least four 
cells were used for each experimental condition in each receptor type.  The number of cells in 
specific experiments is reported in figure legends.  One way ANOVA was applied for statistical 
comparisons and Student’s t-tests were used to calculate pairwise p-values.  
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Atipamezole reversal tests:  To test compounds for α2 adrenergic receptor agonist activity, we 
used the selective α2 adrenergic receptor antagonist atipamezole, at 10 nM and tested for 
reversal of hypnosis in groups of zebrafish larvae (n = 8 or 12 per group).  The 10 nM 
atipamezole concentration was chosen based on concentration-response studies in combination 
with 2.5 x EC50 dexmedetomidine (1.0 µM) and control experiments with other sedative-
hypnotics that confirmed specificity (see Results).  
Statistical Analyses:    Statistical methods used in drug screening and concentration-response 
analysis are described above.  In comparing zebrafish PMR inhibition and tadpole LoRR results, 
the concordance of binary (significant inhibition or not) drug screening outcomes was assessed 
using Cohen’s Kappa with Fisher’s exact test for statistical significance.  Multiple drug potencies 
(mean EC50s or log[EC50s]) in zebrafish vs. tadpoles were compared with Pearson correlations.  
Drug effects on ion channels were compared to positive and negative controls using ANOVA 
with Dunnett’s test for multiple comparisons and pairwise p values were calculated using two-
tailed paired Student’s t-tests.  These analyses and non-linear least squares logistic fits were 
performed using Graphpad Prism 6.  Results are reported as mean ± sd or 95% confidence 
interval (95% CI).  Some graphs display unidirectional 95% confidence intervals, for clarity.  In 
these cases, the confidence intervals are symmetrical around the mean.  There were no missing 
data associated with statistical analyses.  No outlier data were detected in our analyses. 
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Results 
Development of a Photomotor Response Assay using Zebrafish Larvae:  Our initial goal was to 
develop a high-throughput assay for hypnotic drug activity based on stimulus-response in 
zebrafish larvae, and to validate it against standard Xenopus tadpole LoRR tests.  Based on 
prior published work with zebrafish larvae 16,34,35, we tested both acoustic/vibration and photic 
stimuli in larvae ranging in age from 4 to 7 dpf.  Motor responses to acoustic/vibration stimuli 
(taps delivered with a solenoid) were consistent under control conditions, but were not fully 
extinguished by 10 µM etomidate or 10 µM propofol (data not shown), both of which fully inhibit 
righting reflexes in pre-limb bud stage Xenopus tadpoles.  Brief flashes of bright (500 lux) white 
light also elicited motor responses in dark-adapted zebrafish larvae (Fig 2A).  The magnitude of 
activity after photic stimuli was smaller and less consistent than that after tap stimuli, but was 
fully extinguished by either etomidate or propofol at 10 µM.  Experiments in larvae from 3 to 7 
dpf indicated that PMRs were more consistent in older animals with more mature visual systems 
(data not shown).  All subsequent experiments used 7 dpf larvae.  We used a single animal per 
well in 96-well plates, to avoid activity triggered by contact with other moving animals.  
To quantify hypnotic drug effects on the PMR, we first tried averaging the peak activity level 
during and after light stimulus for drug-exposed groups and normalizing to the non-drug control 
group.  However, stimulated activity levels varied widely among animals and among repeated 
trials in single animals (e.g. Fig 2B).  Baseline motor activity also varied among larvae and was 
inhibited by increasing sedative-hypnotic drug concentrations.  To minimize these sources of 
variability and mimic tadpole LoRR tests, we established a rigorous binary outcome for each 
PMR trial.  Each larva’s motor activity in three 0.2 s epochs both during and immediately after 
photic stimulus was compared to the upper 95% confidence interval for spontaneous activity in 
all 0.2 s epochs during pre-stimulus baseline periods (Fig 2B).  By testing each animal in 
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multiple trials, we calculated cumulative PMR probabilities.  Drug effects on spontaneous motor 
activity, as a measure of sedation, were independently analyzed (see below).  
We tested the effect of repeating PMR trials up to 10 times using 96 zebrafish larvae, aiming to 
minimize outcome variance.  Under control conditions, desensitization to the light stimulus was 
observed with repeated trials.  This effect weakened as the inter-trial interval increased from 30 
s to 3 min.  However, intervals of 3 to 12 min all produced similar drops in PMR probability from 
over 90% in the first trial to less than 60% at the 10th trial (Fig 3A; open symbols).  Cumulative 
PMR probability with increasing numbers of trials at 3 min intervals is also shown in Fig 3A 
(solid symbols).  Linear regression analysis indicated a non-zero slope for cumulative PMR 
probability from four trials (slope = -0.0247 ± 0.0022; p = 0.0082) to 10 trials (slope = -0.0301 ± 
0.0009; p < 0.0001).  The cumulative PMR probability variance (standard deviation) remained 
stable for up to four trials, and then monotonically increased with each added trial as the effects 
of desensitization grew (Fig 3B).  Cumulative PMR probability associated with four trials was 
only 7% lower than that from the initial control trial.  Thus, we used four trials with a 3 minute 
interval in subsequent PMR experiments.  With this approach, desensitization to repeated photic 
stimuli was absent in larvae exposed to hypnotic concentrations of etomidate (Fig 3C; slope = -
0.008 ± 0.0195; p = 0.67; n = 12) or equi-hypnotic solutions of dexmedetomidine (slope = -0.002 
± 0.012; p = 0.85; n = 12), ketamine (slope = -0.002 ± 0.019; p = 0.88; n = 12), alphaxalone 
(slope = 0.013 ± 0.019; p = 0.48; n = 12), tricaine (slope = -0.002 ± 0.015; p = 0.86; n = 12) and 
butanol (slope = -0.002 ± 0.019; p = 0.88; n = 12).  These results indicate both that all these 
sedative-hypnotics inhibit mechanisms underlying PMR desensitization to repeated stimuli and 
that a 15 minute drug exposure before PMR testing establishes steady-state drug 
concentrations in larval nervous tissues.   
The optimized PMR assay provided two measures of concentration-dependent drug action in a 
single experiment: sedation measured from inhibition of spontaneous motor activity, and 
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hypnosis from inhibition of the PMR.  Fig 3D shows results and logistic analyses from combined 
data in groups of zebrafish larvae exposed to varying concentrations of etomidate.  Sedation by 
etomidate requires 6-fold lower concentrations than hypnosis, while Hill slopes are comparable 
for both effects.  
Validation of PMR Inhibition Against Tadpole Loss-of-Righting-Reflexes:  Our first validation of 
the zebrafish larva PMR assay used a set of 9 sedative-hypnotic compounds with previously 
published potencies in tadpole LoRR tests: ethanol 36, butanol 36, hexanol 36, ketamine 37, 
propofol 38, etomidate 39, pentobarbital 40, dexmedetomidine 41, and alphaxalone 42.  These 
hypnotics are characterized by LoRR EC50s ranging from low micromolar to high millimolar and 
effects at a variety of molecular targets 14,43.  PMR concentration-response experiments (n = 10 
larvae per condition) showed that for all drugs except dexmedetomidine, EC50 for PMR inhibition 
in zebrafish larvae was within a factor of 3 of the published EC50 for tadpole LoRR (Fig 4A).  
The large discrepancy between the published LoRR EC50 for dexmedetomidine (mean ± sd = 7 
± 1.1 µM) 41 and the PMR EC50 (mean = 0.4.µM) led us to re-test dexmedetomidine in Xenopus 
tadpoles, resulting in EC50 = 0.66 µM (95% CI = 0.28 to 1.56 µM; n = 10 per concentration).  
The Pearson correlation coefficient for drug potencies in zebrafish versus tadpoles (using our 
value for dexmedetomidine in tadpoles) was 0.999 (p < 0.0001), reflecting remarkably close 
agreement.  
To test the utility of zebrafish PMRs in screening new potent hypnotic compounds, we used a 
second group of 11 compounds that were all recently identified as potent modulators of GABAA 
receptors (Table 1), and that had been tested for hypnotic activity and potency using tadpole 
LoRR tests 9.  Results of previous tadpole LoRR tests at 10 µM identified 5 compounds with 
hypnotic activity and six without.  Screening these 11 compounds for hypnotic activity using 
zebrafish PMR assays produced identical positive and negative screening results (Table 2).  
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The concordance of the two approaches was 100% with Cohen’s Kappa = 1.000 (p = 0.0022 by 
Fisher’s exact test).  
Potencies (EC50s) for the five hypnotic GABAA receptor modulators, in both tadpoles and 
zebrafish agreed remarkably closely (Fig 4B; Pearson correlation r = 0.999; p < 0.0001).   
Discovery of new sedative-hypnotic compounds in a drug library screen.  Our second major aim 
was to use zebrafish larvae PMR assays to screen for new sedative-hypnotic compounds in a 
drug library.  We obtained a library of 2651 compounds from the Boston University Center for 
Medical Discovery (Boston, MA USA), including a “diversity set” of 374 compounds selected 
randomly to represent the variety of chemotypes in the larger collection.  We screened the 
diversity set (DS), using 8 larvae per compound, comparing PMR results for up to 10 test 
compounds to a negative (no drug) control group on the same plate.  We found two compounds 
that, at 10 µM, inhibited PMR probability in zebrafish larvae by more than 50%.  Larvae exposed 
to the first of these compounds (DS68; CMLD003288) at 10 µM died within 24 hours of 
exposure.  After confirmation of this toxicity in a second group of zebrafish larvae, we 
discontinued study of this compound.  A second active compound (DS85; CMLD003237; methyl 
((3S,4R,E)-4-nitro-1-phenylpent-1-en-3-yl)carbamate) induced fully reversible PMR inhibition in 
zebrafish larvae at 10 µM (Fig 5A).  A third compound (DS151; CMLD006025; 
(1R,4S,4aS,9aS,11R)-11-hydroxy-3-isopropyl-11-methyl-4,4a,9,9a-tetrahydro-1H-1,4-
ethanofluoren-10-one) produced only about 30% inhibition of PMR when screened at 10 µM 
(Fig 5B).  However, the screening data revealed that this compound inhibited spontaneous 
motor activity by over 90% at 10 µM (Fig 5C).  Re-testing CMLD006025 at 20 µM revealed an 
85% reduction of control PMR probability (mean ± sd = 0.13 ± 0.21 vs 0.83 ± 0.13; p < 0.0001; n 
= 8 per group).   
Characterization of new sedative-hypnotics: Physical properties of CMLD003237 are MW = 
264.1 daltons; calculated LogP = 2.5; polar surface area = 81.5 Å2; 1 H-bond donor; and 3 H-
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bond acceptors.  Concentration-dependent studies of CMLD003237 in zebrafish larvae revealed 
EC50 = 8 µM for inhibition of spontaneous activity and EC50 = 11 µM for inhibition of PMR (Fig 
6A).  A second fresh sample of CMLD003237 was re-tested to confirm activity in zebrafish, and 
a newly synthesized batch was used to test hypnotic effects in Xenopus tadpoles.  
CMLD003237 at up to 30 µM reversibly inhibited tadpole righting reflexes, with an EC50 of 12 
µM (Fig 6B), close to the value for PMR inhibition.  Tadpole LoRR results also confirm that 
CMLD003237 inhibits responses to multiple sensory stimuli.   
To investigate possible molecular mechanisms underlying the sedative-hypnotic actions of 
CMLD003237, we tested effects of hypnotic concentrations (2 x PMR EC50 = 22 µM) on the 
activity of various neuronal receptors that are sensitive to potent sedative-hypnotic drugs and 
also likely mediators of their effects.  CMLD003237 modulated α1β3γ2L GABAA receptors, 
enhancing EC5 GABA-elicited currents by a factor of 3.0 ± 0.50 (Fig 6C; mean ± sd; n =5; p < 
0.0001 by one way ANOVA).  For comparison, an equipotent concentration of etomidate (3.2 
µM) produced much more gating enhancement in GABAA receptors (14 ± 1.7-fold; mean ± sd; 
[95% CI = 12.2 to 16.5]; n = 5; p < 0.0001 vs. both control and CMLD003237).  CMLD003237 
inhibited glycine α1 receptor currents by around 50%, in contrast to positive modulation by 
propofol (Fig 6D).  CMLD003237 did not affect the activity of NR1B/NR2A NMDA receptors (Fig 
6E) and inhibited human α4β2 neuronal nicotinic ACh receptors by around 20% (Fig 6F).  
CMLD003237 inhibited HCN1 currents less than 10% (Fig 6G), but produced no shift in voltage 
sensitivity (Fig 6H). 
To determine whether CMLD003237 acted via α2 adrenergic receptors, we tested whether the 
selective inhibitor atipamezole reversed its hypnotic effects in zebrafish larvae.  To establish 
valid conditions for these experiments, zebrafish were first exposed to dexmedetomidine at 2.5 
x EC50 (1.0 µM; Fig 7A) combined with varying concentrations of atipamezole (0.3 nM to 300 
nM).  This experiment identified 10 nM as the lowest atipamezole concentration that fully 
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reverses dexmedetomidine hypnosis.  Furthermore, 10 nM atipamezole alone produces no 
change in zebrafish larvae PMR probability and no reversal of hypnosis induced with various 
anesthetics that act through other mechanisms (Fig 7B).  Atipamezole produced no reversal of 
CMLD003237-induced hypnosis (Fig 7B). 
Properties of CMLD006025 are MW = 254.1 daltons; calculated LogP = 3.0; polar surface area 
= 37.3 Å2; 1 H-bond donor; and 2 H-bond acceptors.  CMLD006025 was tested for its 
concentration-dependent inhibition of PMRs in zebrafish larvae (Fig 8A) and tadpole LoRRs 
(Fig 8B), resulting in similar EC50s of 13 µM and 10µM, respectively.  Review of the BU-CMD 
library data revealed that CMLD006025 is a highly pure enantiomer and that its mirror image 
enantiomer was another library compound, CMLD011815.  The PMR inhibitory potency of 
CMLD011815 (EC50 > 30 µM; Fig 8C), was lower than that of CMLD006025.  LoRR tests in 
Xenopus tadpoles confirmed that CMLD006025 was more potent than CMLD011815 (Fig 8D).  
We tested equal concentrations (26 µM) of CMLD006025 and CMLD011815 on various ion 
channels, seeking evidence of differential effects that might account for the stereoselective 
hypnotic actions in zebrafish and tadpoles.  GABAA receptor EC5 currents were enhanced 
similarly by both compounds (Fig 8E; 1.5 to 1.7-fold; n = 8 each; both p <0.001 vs. control).  
Glycine α1 receptor EC5 currents were enhanced by propofol, unaffected by CMLD006025, and 
inhibited about 65% by CMLD011815, demonstrating stereoselective effects (Fig 8F). NMDA 
receptor currents were inhibited by ~25% in the presence of either CMLD006025 or 
CMLD011815 (Fig G).  Neuronal nicotinic ACh receptors were also inhibited by ~65% in the 
presence of either compound, without stereoselectivity (Fig 8H).  Human HCN1 receptors were 
inhibited more by CMLD0011815 than CMLD006025, but these effects were both much weaker 
than those of propofol (Fig 8I).  Atipamezole did not reverse the hypnotic effects of either 
enantiomer at equipotent (2 x EC50) concentrations (Fig 8J).    
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The translational potential of CMLD003237 and CMLD006025 as intravenous sedative-
hypnotics was explored in Sprague-Dawley rats.  The dosages and number of animals tested 
was limited by the amount of compounds available.  Three rats were each given a single 
intravenous bolus of CMLD003237 in DMSO, at increasing doses.  The first rat received 9 
mg/kg and displayed no loss of righting reflexes.  A second rat that received 26 mg/kg lost 
righting reflexes 47 s after the injection and returned to an upright prone position after another 
64 s.  A third rat that received a 39 mg/kg intravenous bolus lost righting reflexes 25 s after 
injection and returned to an upright stance after another 5 min 30 s.  However, while the 
hypnotic potencies of CMLD003237 and CMLD006025 were similar in aquatic animals (Figs 6, 
8), CMLD006025 injected intravenously at 40 mg/kg did not impair righting reflexes in rats (n = 
2).    
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Discussion 
Major results:  Goals for developing new sedative-hypnotics include facilitating efficiency in 
outpatient procedural settings and reducing anesthetic toxicities, particularly in vulnerable 
populations 44.  Improving current sedative-hypnotics through rational drug design or 
mechanism-based drug screening strategies may exclude potentially useful drugs that act 
through novel mechanisms.  We have developed and validated a high-throughput stimulus-
response screening approach for sedative-hypnotics in zebrafish larvae and used it in a small 
library of compounds to discover two drugs with reversible sedative-hypnotic activity in aquatic 
vertebrates, with one effective in rodents.  Our novel approach represents a mechanism-
independent primary anesthetic drug discovery strategy based on vertebrate animal stimulus-
response assays. 
Zebrafish Larvae Photomotor Responses vs. Tadpole Loss of Righting Reflexes:  PMRs 
in zebrafish embryos or larvae have been used previously for neuromodulatory drug screening 
experiments 16,45-47.  Embryonic zebrafish responses to intense light stimuli are mediated by 
photosensors in the developing hindbrain, not the eyes 48. Our approach differs from previous 
studies in using zebrafish larvae, which have more developed vision and neural circuits than 
embryos 49, and in specifically measuring both sedation (unstimulated motor activity) and 
hypnosis (inhibition of stimulated motor responses).  Importantly, development of vision in 
zebrafish requires exposure to both light and dark, and visual transduction in larvae shows 
diurnal variation 49,50.  A weakness of our PMR test is the possibility of identifying drugs that 
selectively inhibit visual transduction.  To address this issue, we validated sedative-hypnotic 
effects of both known and novel drugs in Xenopus tadpole LoRR assays.  We can also use 
zebrafish larvae responses to acoustic or tactile stimuli to validate hypnotic drug effects.  
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Our study demonstrated that zebrafish larvae are far more suitable for high-throughput drug 
screening than tadpoles.  Tadpole LoRR assays use about 20 mL of water per animal, so a 10 
µM drug solution for 10 tadpoles requires 2 µmoles.  In comparison, 10 zebrafish larvae, each in 
0.2 mL, require only 20 nmole of drug, 100-fold less than tadpoles.  As a practical constraint, we 
were provided 0.2 µmoles of each drug we screened, ten-fold less than needed for screening at 
10 µM in 10 tadpoles, but ten-fold more than needed for 10 zebrafish larvae.  The zebrafish 
larvae PMR assay also required less glassware and benchtop space in comparison with tadpole 
LoRR tests.  Time and effort required for drug potency assays were also lower for zebrafish 
than tadpoles.  Manually pipetting buffer, animals, and drugs into a 96 well plate took about 30 
minutes, similar to set-up time for multiple groups of tadpoles.  Loading zebrafish larvae into 96-
well plates can be further accelerated through automation 51.  Our computer-controlled PMR 
tests proceeded with multiple trials for up to 96 animals in parallel.  With a 15 minute adaptation 
and equilibration period before four trials at 3 minute intervals, computerized data acquisition 
lasted under 30 min, and analysis of results took under 10 minutes after we developed 
approaches for processing Zebralab outputs for standardized screening and concentration-
response experiments.  In comparable tadpole experiments, each animal was manually tested 
and observed for LoRR for 5 s every 5 minutes for 30 minutes.  This limited a single worker to 
testing no more than 20 animals at a time.  Tadpole LoRR tests also involve a degree of 
judgment, which can introduce bias or error, and with multiple lightly anesthetized animals 
together in a single container, errors related to tracking movements of individual tadpoles 
inevitably occur.  Tadpole results were manually recorded and manually entered for 
computational analysis, introducing additional potential for human error.  
While all healthy tadpoles exhibit brisk righting reflexes in the absence of hypnotic drugs, 
flashing bright white light onto dark-adapted 7 dpf zebrafish larvae did not elicit motor responses 
100% of the time.  We also found that un-drugged larvae exhibited a diminishing PMR 
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probability with repeated trials (Fig 3A).  This desensitization to photic stimuli diminished in the 
presence of hypnotics (Fig 3C), introducing a potential source of bias into concentration-
response analyses.  We minimized this bias by limiting the number of repeated trials to four, 
resulting in a less than 10% drop in control PMR probability, with stable variance (Fig 3A, B).  
Importantly, the absence of desensitization in larvae exposed to hypnotic drugs (Fig 3C) 
indicates that a 15 minute pre-test drug exposure is sufficient to establish steady-state 
pharmacodynamic effects and thus, effect-site concentrations.  Zebrafish larvae desensitization 
to repeated stimuli has also been used as a method for studying learning and memory 35, 
another neural process inhibited by general anesthetics.  In this study, the commercial system 
used to track activity imposed limitations on the time-resolution of video recordings and the 
types of data analyses we could perform.  In future experiments, more refined behavioral 
analyses may be achievable using high-speed video recording and customizable video analysis 
tools for zebrafish behaviors, which are available in public databases 52.   
Our experiments comparing zebrafish larvae PMR tests and tadpole LoRRs indicate that both 
assays provide essentially the same information for drug screening (Table 2) and potency 
determination (Fig 4).  Combined with its advantages in drug sample size and work time, these 
results support adoption of zebrafish larvae as a rapid and reliable platform for screening and 
initial characterization of sedative-hypnotic drugs.  
Discovery of New Potent Sedative Hypnotics in a Drug Library:  Our screen or 374 
compounds from a larger library identified two compounds, CMLD003237 and CMLD006025, 
that reversibly and dose-dependently inhibit both zebrafish larvae PMRs and tadpole righting 
reflexes (Figs 6A & B, and 8A & B).  If the frequency of sedative-hypnotics found in the 
diversity set (0.53%) is representative of all 2651 compounds in the library, then screening the 
remaining compounds should identify another dozen new sedative-hypnotics.  A survey of 
CMLD003237 effects on six neuronal receptors (Figs 6, 7) suggests that both GABAA receptors 
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(Fig 6C) and neuronal nicotinic ACh receptors (Fig 6F) could contribute to its hypnotic actions.  
However, inhibition of glycine receptors by CMLD003027 (Fig 6D) might antagonize its 
anesthetic actions in the spinal cord 53.  Comparing the hypnotic potencies in aquatic animals of 
CMLD006025 and its mirror-image enantiomer, CMLD011815, reveals stereoselectivity (Fig 8A-
D).  Weak modulation of GABAA receptors (Fig 8E), modest inhibition of NMDA receptors (Fig 
8G), and inhibition of neuronal nAChRs (Fig 8H) could all contribute to hypnosis by both 
enantiomers.  The relatively low hypnotic potency of CMLD011815 in animals may be due to its 
inhibition of glycine receptors, which CMLD006025 lacks (Fig 8F).  An intriguing and important 
feature of both CMLD003237 and CMLD006025 is that both apparently act through 
mechanisms different from established potent sedative-hypnotics, such as etomidate, propofol, 
alphaxalone, and dexmedetomidine (Fig 2A), all of which selectively target GABAA receptors or 
α2 adrenergic receptors 43.  Additional molecular mechanisms other than those we tested in this 
initial study may also contribute to the hypnotic effects of these new sedative-hypnotics. 
CMLD003237 and CMLD006025 display similar hypnotic potency in aquatic animals and 
comparable physical properties.  However, exploratory translational experiments in rats 
receiving intravenous injections show that CMLD003237 produces reversible LoRR, while 
CMLD006025 at similar doses does not.  It is not surprising that sedative-hypnotic efficacy in 
small aquatic animals equilibrated for 15 to 30 minutes in a drug solution does not reliably 
predict the effects of bolus intravenous dosing in mammals.  Pharmacokinetic limitations such 
as blood solubility, protein binding, and transport across the blood-brain barrier influence the 
latter far more than the former.  It is conceivable that one or more important targets for 
CMLD006025 differ in rats and the two aquatic species we tested, but this type of 
pharmacodynamic difference is far less likely than a pharmacokinetic difference.  Thus, based 
on these results, we plan to further explore both the unusual hypnotic pharmacology and the 
translational potential of CMLD003237 and its structural variants.  CMLD006025 presents more 
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barriers than CMLD003237 to translational development, while its mechanism of hypnosis is of 
scientific interest.  
Conclusions and Future Directions:  Zebrafish represent an animal model with great potential 
for anesthetic drug discovery as well as basic and translational research on general anesthetics.  
Further screening of drug libraries using the approach we developed is likely to reveal many 
more potent sedative-hypnotics.  Those that act through novel mechanisms will be of great 
scientific interest.  Neuroscience techniques combining recordings from or stimulation of 
neuronal circuit activity 54,55 with behavioral tracking, including photomotor responses, 48 have 
been developed for zebrafish, and these approaches could reveal important details about 
anesthetic mechanisms in neural networks.  Methods for site-directed genetic manipulation of 
zebrafish have also been developed 56-58.  Zebrafish with knockout or site-directed mutations in 
putative anesthetic target genes have the potential to provide new insights into anesthetic 
mechanisms and efficient screening strategies to find target-selective anesthetics.  These 
approaches are being actively explored in our lab. 
[1423 words]  
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Figure 1) Tadpoles vs. Zebrafish Larvae.  A: A glass container holding 5 pre-limb bud stage 
Xenopus tadpoles in 100 mL water.  The polished glass rod, visible in the lower right quadrant 
of the photograph, is used to manually turn the animals during loss-of-righting reflexes tests.   
B:  A 96-well plate loaded with 64 zebrafish larvae, 1 larva per well in 0.2 mL E3 buffer each.  
The inset shows a magnified view of one well containing a 7 dpf larva.  
 
Figure 2)  Photomotor Responses in 7 dpf Zebrafish Larvae.  Activity integration is a 
Zebralab experimental output totaling the number and intensity of pixel changes in a designated 
image area between sequential infrared video sweeps during a 0.2 s experimental epoch (each 
epoch includes 5 video sweeps lasting 0.04 s).  A) Average activity integration for 8 larvae in E3 
buffer with 0.2% DMSO (control conditions) is plotted at 0.2 s intervals during a single 
photomotor response trial.  A 500 lux white light stimulus was activated at 5 s and discontinued 
at 5.2 s (pink bar). Note that activity dramatically increased during the photic stimulus and 
diminished within 1 s.  B) Activity of a single larva during a series of 10 photomotor response 
trials, with 3 minute intervals between trials, is shown.  Pink bars indicate photic stimuli.  The 
purple dashed line indicates the upper 95% confidence interval for mean baseline activity during 
all ten pre-stimulus epochs (5 s each).  Activity during and following photic stimuli was 
consistently above the 95% baseline threshold in all trials, while varying in magnitude from trial 
to trial.  
 
Figure 3)  Photomotor Response Probability and Variance with Repeated Trials are 
Affected by Sedative-Hypnotic Drugs.  A)  Photomotor responses (PMRs) were tested ten 
times with 3 minute intervals between trials in larvae (n = 96) in E3 buffer with 0.2% DMSO (no-
drug control conditions). The single trial PMR probability (open circles; mean ± sd) 
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monotonically decreases with each repetition (trial number) and cumulative PMR probability 
(solid circles; mean ± sd) decreases with the number of included trials, as larvae desensitize to 
the photic stimulus.  Solid lines through the plotted points are linear regression fits, and dashed 
curves are 95% confidence intervals for the fitted lines. The single PMR trial slope (mean ± sd) 
= -0.069 ± 0.0062 and cumulative PMR trial slope = -0.0301 ± 0.0009.  Both slopes are non-
zero (p < 0.0001 by linear regression).  A linear fit to cumulative PMR probabilities for only the 
first four trials gives slope (mean ± sd) = -0.025 ± 0.0022, which is also non-zero (p = 0.0082).  
B) Standard deviations from cumulative PMR probability data in panel A are plotted against trial 
number, showing that variance increases after more than 4 trials.  C)  Single PMR probability 
trial results (mean ± sd; n = 16) in a group of zebrafish larvae exposed to 1.5 µM etomidate and 
tested four times at 3 minute intervals are plotted against drug exposure time, which includes a 
15 minute pre-test exposure period.  The fitted (solid) line to data has a slope (mean ± sd) 
= -0.008 ± 0.020, which is not significantly different from zero (p = 0.67 by linear regression). 
The 95% confidence intervals for the fitted line are drawn as dashed lines. D)  An example of 
experimental results showing etomidate-dependent inhibition of both spontaneous activity (dark 
red triangles) and cumulative PMR probability (red circles).  Points represent mean with 95% 
confidence intervals for 10 animals per concentration, each tested in 4 PMR trials at 3 minute 
intervals.  Lines through data represent logistic fits.  Inhibition of spontaneous activity is 
characterized by EC50 = 0.10 µM (95% CI = 0.080 to 0.12 µM) and nH = 2.0 ± 0.37.  Inhibition of 
PMR probability is characterized by EC50 = 0.6 µM (95% CI = 0.45 to 0.81 µM) and nH = 1.6 ± 
0.40.  
 
Figure 4) Correlation of Hypnotic Potencies in Tadpoles and Zebrafish. A) Zebrafish 
photomotor responses were reversibly inhibited by known anesthetics with potencies closely 
correlated to published tadpole LoRR EC50s (log[EC50] Pearson correlation r=0.999, R2=0.998, p 
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< 0.0001).  Citations for tadpole EC50s are: ethanol 36, butanol 36, hexanol 36, ketamine 37, 
propofol 38, etomidate 39, pentobarbital 40, and alphaxalone 42.  Dexmedetomidine EC50 in 
tadpoles was determined by the authors.   B) In a set of 5 GABAA receptor modulators 
displaying potent hypnotic activity in tadpole screening tests (see Table 2), a very strong 
correlation is observed in comparison to potencies in zebrafish (EC50 Pearson correlation 
r=0.9995, R2=0.999, p < 0.0001).  Table 1 provides citations for the specific compounds, 
indicated by label number.   
 
Figure 5)  Discovery of Novel Sedative-Hypnotics Using Zebrafish Larvae Photomotor 
Responses.  A-C) Bars represent cumulative photomotor response (PMR) probability or 
normalized spontaneous activity from 4 trials at 3 min intervals (mean with symmetrical 95% CI; 
n =8).  A) Screening PMR results from an experiment including negative (E3 with 0.2% DMSO) 
and positive (10 µM etomidate; ETO) control groups, and 6 groups of larvae exposed to test 
compounds at 10 µM.  Diversity Set #85 (DS85; CMLD003237) inhibits larval photomotor 
responses by over 60% (p < 0.0001 by unpaired Student’s t-test).  B)  Screening PMR results 
for DS150 through DS155 are shown.  Note that DS151 (CMLD006025) does not significantly 
inhibit PMR probability (p = 0.045 by unpaired Student’s t-test, above the p = 0.0024 
significance threshold after Bonferroni correction for 7 comparisons).  C)  Spontaneous activity, 
normalized to that of the negative control group from the same experiment shown in panel B.  
DS151 (CMLD006025) inhibited spontaneous activity by over 90% (p < 0.0001 by Student’s t-
test).  D) Chemical structures of CMLD003237, CMLD006025, and CMLD011815, the (-)- 
enantiomer of CMLD006025, are shown.   **** p < 0.0001. 
 
Figure 6) Characterization of CMLD003237 in zebrafish larvae, Xenopus tadpoles, and ion 
channels.  A) Points represent mean with 95% CI for zebrafish larvae (n > 8 per group) 
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photomotor response probability (solid circles) and normalized spontaneous activity (open 
circles).  Lines are logistic fits.  PMR inhibition EC50 = 11 µM (95% CI = 8.2 to 16 µM).  
Spontaneous activity inhibition EC50 = 8 µM (95% CI = 6.1 to 10.5 µM).  B) Tadpole LoRR 
results (n = 8 per group) are shown as binary outcomes.  The line is a logistic fit with EC50 = 12 
µM (95% CI = 9.6 to 14.3 µM).  C to F) Bars represent control-normalized ion channel currents 
(mean with symmetrical 95% CI) measured in Xenopus oocytes.  Currents in the presence of 
CMLD003237 or comparison drugs, both at  2 x hypnotic EC50, were normalized to paired 
control currents in the same oocyte, and outcomes with drugs were compared to controls using 
one way ANOVA.  Panel insets show examples of paired control vs. drug oocyte currents.  C) 
Bars represent control-normalized EC5 GABA-induced currents through human α1β3γ2L 
GABAA receptors.  CMLD003237 (22 µM) enhanced currents elicited with EC5 GABA (3 µM) 
about 3-fold (p = 0.0007; n = 5). An equi-hypnotic etomidate solution (ETO; 3.2 µM) enhanced 
EC5 currents about 14-fold (p < 0.0001; n = 5).  The inset shows currents recorded under all 
three conditions in one oocyte.  D) Bars represent control-normalized EC5 currents through 
human glycine receptor α1 receptors.  CMLD003237 (22µM) inhibited currents elicited with EC5 
glycine (1 µM) about 50% (p = 0.0013; n = 4).  An equi-hypnotic propofol solution (PPF; 4.5 µM) 
enhanced EC5 glycine currents 1.9-fold (p = 0.0010; n = 4).  E)  Bars represent control-
normalized peak currents through human NR1A/2B NMDA receptors.  CMLD003237 (22 µM) 
does not affect control currents elicited with 100 µM NMDA + 10 µM glycine (p = 0.32; n =6), 
while an equi-hypnotic ketamine solution (120 µM) inhibits control currents by about 95% (p = 
0.0002; n = 4).   F)  Bars represent control normalized peak currents through human α2β4 
neuronal nicotinic ACh receptors.  CMLD003237 (22 µM) inhibited control currents elicited with 
1 mM ACh by about 20% (p < 0.0001; n = 9).  Equi-hypnotic ketamine (120 µM) inhibited control 
currents by over 90% (p < 0.0001; n = 8).  G) Plotted symbols represent control-normalized 
peak currents (mean with 95% CI) through human HCN1 receptors.  Raw currents from a single 
oocyte studied under control conditions, with CMLD003237, and with propofol (PPF) are 
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displayed along with an inset showing the voltage-jump activation protocol.  CMLD003237 (22 
µM; n = 8) inhibited control currents by less than 10% at all test voltages. Propofol (4.5 µM; n = 
5) inhibited HCN1 currents by up to 40% in a voltage dependent manner (p < 0.0001 versus 
CMLD003237 at -70 mV).  H) Current traces are tail currents recorded at -40 mV from panel G, 
normalized to the tail current amplitude following activation at -120 mV.  Normalized tail current 
amplitudes (G/Gmax) are also plotted against activation voltage (n = 8 oocytes for 
CMLD003237 and 5 oocytes for propofol).  Lines through these data represent nonlinear 
regression fits to Boltzmann equations.  Fitted propofol control V50 [mean (95%CI) = -79.9 
(-81.0 to -78.8)] differs from control [-73.6 (-72.9 to -74.3); p < 0.001 by F-test].  Fitted 
CMLD003237 V50 [-74.6 (-73.9 to -75.4)] did not differ from control (P= 0.142 by F-test).  ETO: 
etomidate; KET: ketamine; ACh: acetylcholine chloride; PPF: propofol.         
** p < 0.01; *** p < 0.001; **** p < 0.0001.  
 
Figure 7)  Atipamezole reversal of zebrafish photomotor responses is a specific test for 
α2 adrenergic receptor agonism.  A) Atipamezole reverses photomotor response (PMR) 
inhibition by 1.0 µM (2.5 x EC50) dexmedetomidine.  Each bar represents mean and symmetrical 
95% CI of cumulative PMR probability in groups of 12 zebrafish larvae, each tested in four trials.  
One way ANOVA was used to compare the dexmedetomidine group to those exposed to 
atipamezole. Atipamezole at 10 nM or higher concentrations fully reverses dexmedetomidine 
hypnosis (p < 0.0001 vs. dexmedetomidine alone).  B) Atipamezole at 10 nM does not reverse 
photomotor response inhibition by other sedative-hypnotics.  Each bar represents mean and 
95% CI of PMR probability in groups of 8 zebrafish larvae, each tested in four trials.  The black 
bars show the effect of each hypnotic drug at 2.5 x EC50 and the paired gray bar shows the 
effect of the same drug combined with 10 nM atipamezole.  Atipamezole alone does not affect 
the control PMR probability (E3 buffer; p = 0.37), nor does it reverse the hypnotic effects of 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Sedative-Hypnotic Discovery Using Zebrafish Larvae  40 
ketamine (KET; p = 0.84), etomidate (ETO; p = 0.38), tricaine (MS222; p = 0.58), alphaxalone (p 
= 0.36), butanol (p = 0.84), or CMLD003237 (p = 0.65).  ATI = atipamezole; * p < 0.05; ** p < 
0.01; **** p < 0.0001. 
 
Figure 8)  Characterization of CMLD006025 and CMLD011815 in Zebrafish Larvae, 
Xenopus Tadpoles, and Molecular Targets.  A) CMLD006025 inhibition of zebrafish larvae 
photomotor response (PMR) and spontaneous activity. Points represent mean with symmetric 
95% CI (n = 12 per group) and lines are logistic fits.  PMR inhibition (solid squares): EC50 = 13 
µM (95% CI = 9.9 to 16 µM).  Spontaneous activity inhibition (open squares): EC50 = 1.6 µM 
(95% CI = 1.2 to 2.1 µM).  B) Tadpole LoRR results in the presence of CML006025 (n = 8 per 
group), shown as binary outcomes. The line is a logistic fit with EC50 = 10.1 µM (95% CI = 7.2 to 
14.1 µM).  C) CMLD011815 weakly inhibits larval zebrafish PMRs at concentrations above 10 
µM (solid squares; mean with 95% CI; n = 16 per group).  A logistic fit to PMR data did not 
converge.  CMLD011815 inhibition of normalized spontaneous activity is plotted as open 
squares (mean with 95% CI) with logistic fit EC50 = 2.3 µM (95% CI = 1.4 to 3.9 µM).  D) 
Tadpole LoRR results in the presence of CML011815 (n = 8 per group), shown as binary 
outcomes. The logistic fit EC50 is 28 µM (95% CI = 18 to 49 µM).  E to H) Bars represent 
control-normalized ion channel currents (mean with symmetric 95% CI) measured in Xenopus 
oocytes.  Currents in the presence of drugs at  2 x hypnotic EC50 were normalized to paired 
control currents in the same oocyte, and outcomes with drugs were compared to controls using 
one way ANOVA.  Panel insets show examples of paired control vs. drug oocyte currents.  E) 
Bars represent control-normalized EC5 GABA-induced currents through human α1β3γ2L 
GABAA receptors.  CMLD011815 and CMLD006025 (both at 26 µM) similarly enhanced 
currents elicited with EC5 GABA (3 µM) by about 60% (p < 0.001 vs. control; n = 5, for both 
drugs). An equi-hypnotic etomidate solution (ETO; 3.2 µM) enhanced EC5 currents about 14-
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fold (p < 0.0001; n = 5).  F) Bars represent control-normalized currents through human glycine 
α1 receptors.  CMLD011815 (26 µM) inhibited currents elicited with EC5 glycine (1 µM) by 
about 65% (p < 0.0001; n = 4).  In contrast, CMLD006025 (26 µM) did not significantly alter 
current amplitude (p = 0.29; n = 4).  An equi-hypnotic propofol solution (PPF; 4.5 µM) enhanced 
EC5 currents about 1.8-fold (p < 0.0001; n = 4).  G) Bars represent control-normalized currents 
through human NR1A/2B NMDA receptors. CMLD011815 and CMLD006025 (both at 26 µM) 
similarly inhibited currents elicited with 100 µM NMDA + 10 µM glycine by about 25% (p < 
0.0001; n = 4 for both drugs).  An equi-hypnotic ketamine solution (KET; 120 µM) inhibited 
currents about 95% (p < 0.0001; n = 4).  H)  Bars represent control-normalized currents through 
human α4β2 neuronal nicotinic ACh receptors.  CMLD011815 and CMLD006025 (both at 26 
µM) similarly inhibited currents elicited with1 mM ACh by about 65% (p = 0.0001; n = 4 for both 
drugs).  An equi-hypnotic ketamine solution (KET; 120 µM) inhibited currents over 90% (p < 
0.0001; n = 4).  I) Symbols represent control-normalized peak currents (mean with 95% CI) 
through human HCN1 receptors.  Currents were inhibited less than 10% in the presence of 26 
µM CMLD006025 (n = 9), while an equal concentration of CMLD011815 (n = 9) inhibited 
currents by about 18% with activation at -70 mV.  An equi-hypnotic solution of propofol (PPF; 
4.5 µM; n = 5) inhibited HCN1 currents by over 40%.  Boltzmann nonlinear regression of G/V 
relationships (not shown) indicate V50 shifts with both propofol (P< 0.0001 by F-test; n = 5) and 
with CMLD011815 (P = 0.0015 by F-test), but not with CMLD006025 (both P = 0.11 by F-test).  
J) Bars represent zebrafish larvae PMR responses (mean with 95%CI; n = 12 per group) 
measured in the absence and presence of atipamezole (10 nM).  Atipamezole reverses PMR 
inhibition by dexmedetomidine (1.0 µM; p = 0.0001 by unpaired Student’s t-test), but not by 
equi-hypnotic concentrations of CMLD011815 (70 µM; p = 0.86) or CMLD006025 (33 µM; P > 
0.999).  
ETO = etomidate; PPF = propofol; KET = ketamine; *** P< 0.001; ****P< 0.0001. 
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Table 1. Potent GABAA Receptor Modulators Tested in Tadpoles and Zebrafish Larvae 
 
Compound #  Reference Name of Compound in 
Reference 
1 Ramerstorfer et al. 20 CGS-9598 
2 Middendorp et al. 8  Compound 11 
3 Kopp et al. 21 Valerenic Acid Derirative-10 
4 Middendorp et al. 8  Compound 20 (Structure not 
shown) 
5 Maldifassi et al. 9 Compound 31 
6 Maldifassi et al. 9  Compound 132 
7* PubChem Compound Database PubChem CID: 43947938 
8 Middendorp et al. 8 Compound 67 
9 Baur et al. 22 4-O-methylhonokiol 
10* PubChem Compound Database PubChem CID: 18593928 
11* PubChem Compound Database PubChem CID: 3878620 
 
* Compounds 7, 10, and 11 have not been described in previous publications.  Modulation of 
GABAA receptors by these compounds was confirmed by Constanza Maldifassi, PhD (Centro 
Interdisciplinario de Neurociencia de Universidad de Valparaíso, Valparaíso, Chile; personal 
communication). Compound information and available commercial vendors can be found in 
PubChem Compound Database (https://pubchem.ncbi.nlm.nih.gov/ ). 
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Sedative-Hypnotic Discovery Using Zebrafish Larvae Table 2 
 
Table 2:  Zebrafish vs. Tadpole Screening for Hypnotic Activity in GABAA Receptor 
Modulators 
 
 
 
Zebrafish  
PMR 
Tadpole LoRR 
 Yes No Total 
Yes 5 0 5 
No 0 6 6 
Total 5 6 11 
 
A set of 11 potent GABAA receptor modulators (see Table 1 for details and references) were 
scored as demonstrating or lacking hypnotic activity at 10 µM.   Manual tadpole LoRR tests 
were scored as positive if 5 or more of 10 animals lost righting reflexes after 30 min of 
immersion in test solution.  Zebrafish larvae PMR inhibition was performed on 8 animals per 
compound with 5 or 6 experimental drugs simultaneously tested against a negative control (E3 
buffer with 0.2% DMSO) and a positive control (10 µM etomidate).  The PMR outcomes were 
scored based on ANOVA comparisons to the negative control group (p < 0.05).   Concordance 
between zebrafish larva PMRs and tadpole LoRRs for identifying hypnotics among this group 
of compounds was 100% (Cohen’s Kappa = 1.000; p = 0.0022 by Fisher’s exact test). 
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